Selank and Semax: Nootropic Peptides Under Investigation

Selank and Semax are two synthetic peptides originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are derived from naturally occurring regulatory peptides and have been the subject of extensive preclinical research investigating their effects on cognitive function, neuroprotection, and immune modulation. This article reviews the published research on both peptides.

Selank

Background and Structure

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with the addition of a C-terminal Pro-Gly-Pro sequence that stabilizes the peptide against enzymatic degradation and extends its biological half-life.

Molecular weight: 751.9 Da

Origin: Derived from tuftsin, a tetrapeptide produced by enzymatic cleavage of the heavy chain of IgG

Classification in research: Studied as an anxiolytic and immunomodulatory peptide

Immunomodulatory Research

Selank's parent compound, tuftsin, is an established immunomodulatory peptide. Research has investigated whether Selank retains and extends these properties:

In-vitro findings:

• Selank modulated the production of pro-inflammatory and anti-inflammatory cytokines in cultured immune cells
• Treatment of monocyte cultures with Selank altered the expression of IL-6, IL-1beta, and TNF-alpha in a concentration-dependent manner
• Studies using splenocyte cultures demonstrated effects on T-cell proliferation and differentiation markers

Animal model findings:

• In immunosuppressed mouse models, Selank administration was associated with partial restoration of immune function parameters
• In viral challenge models (using non-pathogenic strains), Selank-treated animals showed modulated antiviral immune responses
• Gene expression analysis in treated animals revealed alterations in approximately 50 genes related to immune function, including chemokine and cytokine signaling pathways

Anxiolytic Research

A substantial body of animal research has investigated Selank's effects on anxiety-related behaviors:

Behavioral studies:

• In the elevated plus maze (a standard anxiety test in rodents), Selank-treated animals spent significantly more time in open arms compared to controls, consistent with an anxiolytic-like effect
• In the light-dark box test, Selank increased the time spent in the illuminated compartment
• In conflict paradigms (Vogel test), Selank increased the number of punished responses, suggesting reduced anxiety-related behavioral suppression
• These anxiolytic-like effects were observed without the sedation, muscle relaxation, or motor impairment typically associated with benzodiazepine compounds in animal models

Proposed anxiolytic mechanisms:

• Modulation of GABAergic neurotransmission — studies suggest Selank may influence GABA-A receptor function, though the mechanism appears distinct from benzodiazepine binding
• Influence on monoamine metabolism — changes in serotonin and dopamine turnover have been observed in specific brain regions of treated animals
• Modulation of BDNF (brain-derived neurotrophic factor) expression in hippocampal tissue

Cognitive Research

Limited studies have investigated Selank's effects on cognitive function in animal models:

• In passive avoidance learning tasks, Selank-treated rodents showed improved retention compared to controls
• In spatial navigation tasks (Morris water maze), some studies reported improved acquisition and memory consolidation in treated animals
• Gene expression profiling of hippocampal tissue from treated animals revealed modulation of genes involved in synaptic plasticity and neurotransmission

Semax

Background and Structure

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of the endogenous neuropeptide ACTH(4-10) — a fragment of adrenocorticotropic hormone that retains neurotrophic and neuroprotective properties without the hormonal (adrenal-stimulating) activity of full-length ACTH. Like Selank, Semax has a C-terminal Pro-Gly-Pro extension for metabolic stability.

Molecular weight: 813.93 Da

Origin: Derived from ACTH(4-10), the melanocortin receptor-active fragment of ACTH

Classification in research: Studied as a nootropic and neuroprotective peptide

Neuroprotection Research

Semax has been studied most extensively in the context of neuroprotection:

In-vitro findings:

• In cultured cortical neurons exposed to oxidative stress (H2O2), Semax treatment was associated with improved cell survival compared to untreated controls
• In glutamate excitotoxicity models, Semax demonstrated protective effects on neuronal viability
• Gene expression studies in neuronal cultures treated with Semax identified upregulation of neurotrophic factors including BDNF, NGF, and NT-3

Animal model findings (cerebral ischemia):

• In rat models of middle cerebral artery occlusion (MCAO), Semax-treated animals showed reduced infarct volumes compared to controls
• Treated animals demonstrated improved neurological function scores in post-ischemia behavioral assessments
• Gene expression profiling of ischemic tissue from Semax-treated animals revealed modulation of immune and inflammatory pathways, vascular remodeling genes, and neurotrophic factor expression
• A large-scale transcriptome analysis identified over 1,000 genes with altered expression in response to Semax treatment in the ischemic brain, with particularly prominent effects on immune response, vascular function, and neuronal survival pathways

Cognitive Enhancement Research

Animal studies on learning and memory:

• In active avoidance learning paradigms, Semax-treated rodents showed accelerated acquisition of the conditioned response
• In the Morris water maze, some studies reported improved spatial learning and memory consolidation in treated animals
• In aged animal models, Semax partially restored cognitive performance toward levels observed in younger animals on certain tasks

Proposed cognitive mechanisms:

• Enhanced expression of BDNF and other neurotrophins in hippocampal and cortical regions
• Modulation of acetylcholinergic neurotransmission — some studies report increased acetylcholine turnover in treated animals
• Effects on dopaminergic and serotonergic systems — changes in monoamine levels have been observed in specific brain regions
• Influence on synaptic plasticity-related gene expression

Neurotrophic Factor Research

One of the most consistently reported effects of Semax across studies is the upregulation of neurotrophic factors:

• BDNF (Brain-Derived Neurotrophic Factor): Multiple studies report increased BDNF mRNA and protein levels in hippocampus and cortex of Semax-treated animals
• NGF (Nerve Growth Factor): Upregulation observed in basal forebrain and hippocampal tissue
• NT-3 (Neurotrophin-3): Increased expression in several brain regions
• CNTF (Ciliary Neurotrophic Factor): Upregulation reported in glial cell cultures

The convergence of evidence around neurotrophic factor upregulation provides a plausible mechanism linking Semax to both neuroprotective and pro-cognitive effects observed in animal models.

Comparative Analysis

Similarities

• Both are synthetic heptapeptides with a stabilizing Pro-Gly-Pro C-terminal extension
• Both were developed at the same Russian research institute
• Both demonstrate effects on gene expression related to neurotrophic factor production
• Both have been studied primarily in rodent models
• Both appear to affect anxiety-related behaviors in animal models, though through potentially different mechanisms
• Neither shows evidence of tolerance development in available animal studies

Differences

Limitations of Current Research

Geographic Research Concentration

A significant limitation of both Selank and Semax research is that the majority of published studies originate from Russian research groups. While these publications appear in legitimate peer-reviewed journals, the concentration of research within one geographic and institutional network limits the independent replication that strengthens scientific consensus.

Language and Access Barriers

Some relevant studies are published in Russian-language journals that may not be fully accessible to the international research community. This creates potential gaps in systematic reviews and meta-analyses.

Mechanistic Gaps

For both peptides, the precise molecular mechanisms remain incompletely characterized:

• Neither peptide has a definitively identified primary receptor in the brain
• The relationship between immune modulatory and cognitive effects is not well understood
• Dose-response relationships have not been fully characterized for all reported endpoints

Translational Uncertainty

• All available efficacy data comes from animal models and in-vitro studies
• The pharmacokinetic properties in larger animal models are not well established
• Long-term safety data from animal studies is limited

Research Peptide Quality Considerations

For researchers working with Selank and Semax:

• Purity: >95% by HPLC minimum; >98% recommended for behavioral studies where dose precision matters
• Identity verification: Mass spectrometry confirmation is essential, particularly given the similar molecular weights and sequences
• Stability: Both peptides should be stored lyophilized at -20C. Reconstituted solutions in BAC water are typically stable for 14-21 days at 2-8C
• Reconstitution: Both dissolve readily in bacteriostatic water or sterile water at standard research concentrations
• Methionine sensitivity (Semax): The N-terminal methionine residue in Semax is susceptible to oxidation. Protect reconstituted solutions from light and dissolved oxygen.

Conclusion

Selank and Semax represent an interesting class of synthetic peptides derived from endogenous regulatory sequences. The available preclinical research suggests distinct but complementary activity profiles — Selank primarily in anxiolytic and immunomodulatory domains, Semax primarily in nootropic and neuroprotective domains. The convergence of evidence around neurotrophic factor modulation provides a mechanistic framework that warrants further investigation. However, the geographic concentration of research and the absence of independent replication by Western laboratories remain significant caveats. Researchers are encouraged to critically evaluate the primary literature and prioritize high-purity, well-characterized material for their studies.

This article is a review of published research literature for educational purposes only. Selank and Semax are research peptides for laboratory use only and are not intended for human consumption. No therapeutic claims are made or implied.